– New real-world analysis highlights unmet medical need in GI cancer patients with TSC1/2 alterations- LOS ANGELES, Jan. 19, 2024 /PRNewswire/ — Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients…